Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciclesonide Onset of Action in SAR (EEC Study)
NCT00659594Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Primary completion
- Feb 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing Ciclesonide 200µg with Placebo (2 arms). Primary endpoint: Time to onset of action at 14 hours. Started Nov 2004; status: completed.
02
Drugs
ciclesonide
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00659594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00659594.